Inherited retinal diseases (IRDs) are a clinically and genetically heterogeneous group of rare diseases. Whilst pathogenic variants in some genes account for many thousands of affected individuals worldwide, others are less recurrent. At the level of the genetic variant itself, the heterogeneity is even larger. Technological advancements in molecular intervention strategies have enabled the successful development of genetic therapies for a few selected subtypes of IRD, with encouraging results. Yet, the genetic and allelic heterogeneity, different types of intervention strategies, and the suitability of clinical endpoints in different trials pose a challenge on the development of interventions for rare and ultrarare forms of IRD. During this presentation, I will provide some latest scientific insights in different intervention strategies, but also highlight the opportunities and challenges, to discuss the road ahead towards successful implementation of personalized interventions for IRD.